Extrapulmonary Neuroendocrine Carcinoma
📧 Sign up to get email alerts when something new happens for Extrapulmonary Neuroendocrine Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease [Phase 1]
A Phase 1 clinical trial evaluating a patient-derived autologous B7-H3 CAR-T cell therapy in previously treated extensive-stage small cell l…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung [Phase 2, Phase 3]
A National Cancer Institute-sponsored trial is evaluating adding atezolizumab to standard chemotherapy for advanced or metastatic extrapulmo…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating Tarlatamab and Sacituzumab Govitecan in previously treated extensive-stage…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy [Phase 3]
Phase 3 trial evaluating Obrixtamig plus carboplatin and etoposide versus standard chemotherapy for unresectable locally advanced or metasta…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of Tarlatamab in patients with advanced extrapulmonary neuroendocrine carcinomas, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial of the DLL3-targeting radiopharmaceutical [212Pb]Pb-DOTAM-MAM279 (MP0712) in small cell lung cancer and other DLL…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma [Phase 2]
A Phase 2 study is evaluating the efficacy and safety of a triple combination of chidamide, sintilimab, and bevacizumab as second-line thera…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC [Phase 2]
This Phase II trial investigates Benmelstobart in combination with Anlotinib and chemotherapy as first-line therapy for large-cell neuroendo…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) [Phase 1]
Phase 1 first-in-human study of ML261, an autologous DLL3-targeted CAR T cell therapy, in relapsed/refractory small cell lung cancer and sel…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection [Phase 2]
Phase 2 trial assessing the imaging tracer 18F-FAPI-74 for cancer detection across multiple indications; currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors [Phase 1]
Phase 1 clinical trial update on the investigational agent BL-M14D1 for locally advanced or metastatic small cell lung cancer and a range of…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: TAS-102 in Extrapulmonary Neuroendocrine Carcinoma [Phase 2]
Phase 2 trial of TAS-102 for extrapulmonary neuroendocrine carcinoma was terminated.
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]
Phase 1/2 SKYBRIDGE study evaluating Peluntamig (PT217) in DLL3-expressing neuroendocrine carcinomas; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-03-14Clinical Trial Update: Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma [Phase 2]
A Phase 2 trial evaluating nab-paclitaxel in combination with bevacizumab for metastatic extrapulmonary neuroendocrine carcinoma has complet…
-
CLINICAL_TRIALS trial_result · 2021-12-03Clinical Trial Update: Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas [Phase 2]
Phase 2 trial evaluating camrelizumab with chemotherapy and apatinib in extrapulmonary neuroendocrine carcinomas is ongoing with unknown sta…